BCIQ Profiles

Company Profile Report

Valo: adding tumor antigens to oncolytic viruses

Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies.

Oncolytic viruses kill cancer cells by lysing the cells, and are engineered to amplify antitumor immune responses through expression of immuno-stimulatory genes.

By adding targeted antigens to viral surfaces, Valo Therapeutics Ltd. thinks the viruses can get a more specific antitumor response.

CEO Michael Stein said the

Read the full 703 word article

How to gain access

Continue reading with a
two-week free trial.